- Correction
- Open Access
- Published:
Correction to: Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy
Molecular Brain volume 13, Article number: 50 (2020)
Correction to: Mol Brain (2019) 12:92
https://doi.org/10.1186/s13041-019-0513-9
Following publication of the original article [1], the authors reported errors in Fig. 4. Specifically, a wrong actin blot is presented in Fig. 4a. In this Correction, the corrected version of Fig. 4 is shown.
The R214C mutation resulted in reduced surface and total expression levels of the α1 subunit, and altered the kinetic and single channel properties of GABAARs. a Representative blots of biotinylation samples for surface receptor expression and cell lysates for total receptor expression from HEK293 cells expressing either WT or R214C GABAARs. b Quantification of surface α1 subunits normalized to Na+/K+ ATPase (n = 6), and total α1 subunits normalized to β-actin (n = 10). Statistical differences were determined using student’s t-test by comparing to expression levels of WT GABAAR expressing cells (***p < 0.001). c Representative traces of GABA currents recorded in excised macro-patch membrane under outside-out configuration from WT or R214C GABAAR expressing cells. Currents were evoked by rapidly perfusion of 10 mM GABA to the membrane patch for 400 ms. Quantification of averaged peak current amplitudes (d), 10–90% rise time (e), deactivation rate (f) and desensitization (g) in WT (n = 8) or R214C (n = 8) GABAAR expressing cells. h Representative single channel current traces recorded under cell-attached configuration with a pipette containing GABA (1 mM) at a holding potential of + 100 mV from cells expressing WT or R214C GABAARs. Quantified average of conductance (i), opening frequency (j), mean open time (k), total open time (l), total closed time (m), and open channel probability (n) of WT (n = 10) or R214C (n = 13) GABAARs. Statistical differences were determined using student’s t-test by comparing to WT GABAAR cells (*p < 0.05, **p < 0.01, ***p < 0.001)
Reference
Bai YF, et al. Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy. Mol Brain. 2019;12:92. https://doi.org/10.1186/s13041-019-0513-9.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Bai, YF., Chiu, M., Chan, E.S. et al. Correction to: Pathophysiology of and therapeutic options for a GABRA1 variant linked to epileptic encephalopathy. Mol Brain 13, 50 (2020). https://doi.org/10.1186/s13041-020-00593-6
Published:
DOI: https://doi.org/10.1186/s13041-020-00593-6